The Scoop: St. Jude to Build a Collab-Fostering Research Hub
Ground Will Be Broken for a 625,000-Square-Foot Facility to Be Completed in 2021
Top 10 Under 40
Biopharma Research and Businesses Benefit from Contributions of Emerging Leaders
Breaking NGS Ground
CMS Final Coverage Determination Promotes Sequencing-Based Testing for Advanced Cancer
Mass Spec Is Being Souped Up to Help It Keep Up
A Few Modifications Might Enhance Performance
For full access to this article login to GEN Select now.
Supplement: Who Gets Immunotherapy for Cancer?
Managing Patient Expectations Requires Better Biomarkers and Companion Diagnostics
- Single-agent or combination checkpoint inhibition (CPI) immunotherapy can have dramatic impacts for positive responders. But currently used nonspecific biomarkers are unable to definitively stratify and identify cohorts. This is a critical challenge; no one wants to deny care. Targeted biomarkers and companion diagnostics can greatly aid therapeutic decision making. ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.